Eris Lifesciences · NSE: ERIS · BSE: 540596
Q1 FY21 results · Apr–Jun 2020
Eris Lifesciences reported revenue from operations of ₹293.24 crore (up 6.9% from Q1 FY20) and net profit of ₹89.02 crore (up 5.9% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 293.24 | 274.30 | +6.9% | 248.57 | +18.0% |
| Other income | 1.34 | 2.83 | −52.6% | (1.07) | Turned profit |
| Total income | 294.58 | 277.13 | +6.3% | 247.50 | +19.0% |
| Profit before tax | 94.64 | 94.92 | −0.3% | 61.50 | +53.9% |
| Net profit for the period | 89.02 | 84.06 | +5.9% | 56.27 | +58.2% |
| EPS, basic (₹) | 6.56 | 6.11 | +7.4% | 4.13 | +58.8% |
| Net margin (%) | 30.4 | 30.6 | 22.6 |
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 261.48 | 262.33 | −0.3% | 230.74 | +13.3% |
| Other income | 1.41 | 2.72 | −48.1% | (0.80) | Turned profit |
| Total income | 262.89 | 265.04 | −0.8% | 229.94 | +14.3% |
| Profit before tax | 92.16 | 92.04 | +0.1% | 59.22 | +55.6% |
| Net profit for the period | 87.13 | 81.96 | +6.3% | 55.11 | +58.1% |
| EPS, basic (₹) | 6.42 | 5.96 | +7.7% | 4.05 | +58.5% |
| Net margin (%) | 33.3 | 31.2 | 23.9 |
Consolidated
- Filed with BSE
- 04 Aug 2020, 19:41 IST
- Board meeting
- 04 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 04 Aug 2020, 19:41 IST
- Board meeting
- 04 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE